ArticleEClinicalMedicine2020
Safety and immunogenicity evaluation of recombinant BCG vaccine against respiratory syncytial virus in a randomized, double-blind, placebo-controlled phase I clinical trial.
Article in EClinicalMedicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed, 3 syntheses or guidelines pooled it, 55 citations in OpenAlex.
- Efficacy and safety of respiratory syncytial virus vaccines.The Cochrane database of systematic reviews · 2025Pooled it
- Vaccines for the common cold.The Cochrane database of systematic reviews · 2022Pooled it
- The immunogenicity and safety of respiratory syncytial virus vaccines in development: A systematic review.Influenza and other respiratory viruses · 2021Pooled it
- A recombinant BCG vaccine induces specific immunity against respiratory syncytial virus andEmerging microbes & infections · 2026Article
- Long-term stability of the GMP-compliant recombinant BCG vaccine against human RSV under quality control analyses.iScience · 2026Article
- Maternal Influenza Vaccine Reduces the Risk of Respiratory Syncytial Virus and Related Respiratory Hospitalizations in Early Infancy: An Epidemiological Study.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026Article
- A comprehensive look at Respiratory Syncytial Virus (RSV): from pathogenesis to prevention.Tropical diseases, travel medicine and vaccines · 2026Review
- Catching our breath: development of interventions and therapies for respiratory syncytial virus.Microbiology and molecular biology reviews : MMBR · 2026Review
- Regulation of antiviral immunity by PD-1 during respiratory syncitial virus infection and upon vaccination.iScience · 2026Article
- Live Attenuated Influenza Virus as a Vector for Multivalent T-Cell Vaccines: Targeting RSV, hMPV, and PIV3.Vaccines · 2026Article
- Respiratory Syncytial Virus (RSV): A Comprehensive Overview From Basic Biology to Clinical Prevention and Control.Medicinal research reviews · 2026Review
- RSV vaccine development: advances and fusion protein-focused strategies.Frontiers in immunology · 2026Review
- Review
- Unleashing the power of the BCG vaccine in modulating viral immunity through heterologous protection: A scoping review.Human vaccines & immunotherapeutics · 2025Article
- NOD2 (Nucleotide-Binding Oligomerization Domain-Containing Protein 2)-Mediated Modulation of the Immune Response Induced by BCG (Bacillus Calmette-Guérin) Bacilli.Pathogens (Basel, Switzerland) · 2025Article
- Recombinant BCG Expressing IL-12 as A Novel Immunomodulatory Strategy for Allergic Asthma: Opportunities and Challenges.Clinical reviews in allergy & immunology · 2025Review
- Review
- Beyond Tuberculosis: The Surprising Immunological Benefits of the Bacillus Calmette-Guérin (BCG) Vaccine in Infectious, Auto-Immune, and Inflammatory Diseases.Pathogens (Basel, Switzerland) · 2025Review
- Role of Trained Immunity in Heath and Disease.Current cardiology reports · 2025Review
- The respiratory syncytial virus vaccine and monoclonal antibody landscape: the road to global access.The Lancet. Infectious diseases · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRespiratory syncytial virus (RSV) is responsible for most respiratory tract infections and hospitalizations in infants and represents a significant economic burden for public health. The development of a safe, effective, and affordable vaccine is a priority for the WHO.
methodsWe conducted a double-blinded, escalating-dose phase 1 clinical trial in healthy males aged 18-50 years to evaluate safety, tolerability, and immunogenicity of a recombinant
findingsThe rBCG-N-RSV vaccine was safe, well-tolerated, and no serious adverse events related to the vaccine were recorded. Serum IgG-antibodies directed against
interpretationThe rBCG-N-hRSV vaccine had a good safety profile and induced specific cellular and humoral responses.
fundingThis work was supported by Millennium Institute on Immunology and Immunotherapy from Chile (P09/016), FONDECYT 1190830, and FONDEF D11E1098.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.